Efficacy and safety of 177Lutetium-prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer patients: First experience in West Asia – A prospective study

Efficacy and safety of 177Lutetium-prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer patients: First experience in West Asia – A prospective study

Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is highly expressed on the surface of prostate cancer (PC) cells, making it an excellent radiotracer for both therapeutic and diagnostic purposes. In this prospective study, we investigated the efficacy and toxicity of 177Lute...

Full description

Bibliographic Details
Main Authors: Ramin Akbarian Aghdam, Mahasti Amoui, Mohammadali Ghodsirad, Sepide Khoshbakht, Bahram Mofid, Fateme Kaghazchi, Mehrdad Tavakoli, Elahe Pirayesh, Hojjat Ahmadzadehfar
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2019-01-01
Series:World Journal of Nuclear Medicine
Subjects:
177Lutetium
metastatic castration-resistant prostate cancer
prostate cancer
prostate-specific membrane antigen
radionuclide therapy
theranostic
Online Access:http://www.wjnm.org/article.asp?issn=1450-1147;year=2019;volume=18;issue=3;spage=258;epage=265;aulast=Aghdam

Internet

http://www.wjnm.org/article.asp?issn=1450-1147;year=2019;volume=18;issue=3;spage=258;epage=265;aulast=Aghdam

Similar Items